Full Press Release Details
Oncolytics Biotech Inc. Announces Participation
in World Immunotherapy Congress USA 2017
CALGARY, May 23, 2017 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC)
(OTCQX:ONCYF) (Oncolytics or the Company) today announced that Dr. Andres A. Gutierrez, Chief Medical Officer of Oncolytics Biotech
Inc. will present at the World Immunotherapy Congress USA 2017 in a session on Tuesday, May 23rd, 2017 at 3:20 pm
PT. Dr. Gutierrez's presentation will focus on the use of "REOLYSIN as potential novel immuno-oncology
viral agent for the anti-cancer armamentarium". The conference takes place on May 23rd and 24th at the Hilton San Diego Resort
and Spa in San Diego, CA.
"As the only company that has evaluated an intravenously-administered
oncolytic virus in hundreds of cancer patients, Oncolytics is eager to share our experience with the scientific and clinical communities
to support the development of oncolytic viruses for improved patient outcomes," said Dr. Gutierrez. "Our presentation
will demonstrate that REOLYSIN is a true immuno-oncology agent that in addition to causing tumor cell lysis, generates innate and
adaptive anti-tumor immune responses. We will address the debate surrounding different clinical endpoints in immuno-oncology studies
as we present our emerging safety and positive efficacy data in combination with chemotherapy in breast and pancreatic cancer trials.
We are also excited to share our plans for a registration study in metastatic breast cancer, and discuss next generation trials
of REOLYSIN in combination with checkpoint inhibitors and IMID's."
More information regarding the presentation is available at:
About the World Immunotherapy Congress USA
Following a successful launch in Europe, World Immunotherapy Congress has added a U.S. event. Co-located with Americas Antibody
Congress 2017, World Biosimilar Congress USA, and Cell Culture World Congress USA. World Immunotherapy Congress USA presents the
unique opportunity for pharma, biotech, government, academia, and their partners to get the latest updates on both clinical and
pre-clinical developments in checkpoint inhibitors, cell therapy, and oncolytic viral immunotherapy. It is where science meets
business to make immunotherapy the cornerstone of the fight against cancer.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, an immuno-oncology viral-agent, as a potential treatment for a variety
of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive
immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy
combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator
(IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in
breast cancer, as well as studies in combination with checkpoint inhibitors and IMID/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session times are subject to change. This release and
the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties
and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company
to be materially different from the results, performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and
timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and
uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2017/23/c5806.html
For further information: Oncolytics Investor & Media Contact:
Oncolytics Biotech Inc., Michael Moore, Vice President, Investor Relations & Corporate Communications, 858-886-7813, mmoore@oncolytics.ca
CO: Oncolytics Biotech Inc.
CNW 07:00e 23-MAY-17